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HIGHLIGHTS
Multi-parameter and genomic tests in breast cancer are undergoing rapid development and implementation in lymph node negative breast cancer. There remains substantial uncertainty about the efficacy and cost-effectiveness of such tests when used in higher risk patients.
There are major challenges in undertaking meaningful research to inform reimbursement and adoption decisions for these diagnostic tests and for personalised medicine technologies in general.
In this context, we describe how the use of value of information analysis as the primary outcome of a randomised controlled feasibility trial, in the presence of multiple competing technologies, has led to the setup of a major national study which is directly designed to inform an estimate of the cost-effectiveness of a personalised treatment strategy in clinically high risk early breast cancer.
BACKGROUND
There is increasing concern in developed nations that health care costs are increasing at an unsustainable rate. Precision medicine has been heralded as a solution by providing more effective treatments to smaller targeted patient populations. In the context of breast cancer, adjuvant chemotherapy is offered to most women with invasive breast cancer involving the axillary lymph nodes or with otherwise clinically high risk disease. [1] [2] [3] [4] As a universal recommendation chemotherapy is, however, not strongly supported by randomised clinical evidence in women who are post-menopausal, of older age and who have oestrogen receptor (ER) positive HER2 negative cancer. 5 It is therefore likely that many women with ER positive breast cancer are being offered chemotherapy with only limited benefit and substantial risk of harm. [6] [7] [8] Diagnostic tests that help identify which women can safely avoid chemotherapy could improve health outcomes as well as ease the pressure on strained health system budgets.
Molecular tests may select patients who can safely be spared chemotherapy under the rationale that the sensitivity of tumours to chemotherapy is dependent on underlying cancer biology, not just clinical and pathological factors. Such new technologies are evolving rapidly with an increasing number of commercial and academic institutions offering solutions.
Different tests contain different combinations of molecular markers and identify different patients as at high or low risk of recurrence, but their comparative diagnostic properties remains largely unknown.[Ref -not all tests are equal] The maturity of evidence for these tests is very variable and traditional methods for generating level one evidence may lack efficiency. There is a risk that technologies entering the market first will be adopted, thereby stifling the development of evidence for alternative tests that are currently less well developed but which may emerge as better tests for widespread implementation in the future.
A prospective randomised controlled trial is necessary to measure the clinical utility and costeffectiveness of molecular testing in this patient population. Such a trial requires large numbers of patients with at least 5 years of follow-up to capture relevant outcomes. The randomised comparison of multiple tests in this context is likely to be prohibitive in terms of scale and cost. Realistically there are only enough resources available to study one test in an adequately powered trial. It is essential that a test chosen to be to focus of such a trial is that which has the highest likely long term societal return on that research investment.
OPTIMA prelim (ISRCTN42400492) 9 was established as a feasibility trial prior to an adequately powered phase three randomised controlled trial of molecular testing in early breast cancer in the UK (Figure Supplementary 1) . The objectives were: (i) to evaluate the performance and health-economics of alternative molecular tests to determine which technology(s) are to be evaluated in a subsequent main trial; (ii) to establish the acceptability to patients and clinicians of randomisation to test-directed treatment assignment; and (iii) to establish efficient and timely sample collection and analysis essential to the delivery of molecular tests driven treatment. We report here the results of the health-economic analysis and value of information analysis designed to inform the selection of a test for study in the subsequent OPTIMA trial.
METHODS

The OPTIMAprelim trial
The design of OPTIMA prelim is described in the protocol available to download on the funder's website (http://www.nets.nihr.ac.uk/projects/hta/103401). Eligible patients were women aged ≥40 with ER positive, HER2 negative clinically high risk (1-9 axillary lymph nodes involved, or node negative with a tumour ≥30mm) surgically treated early invasive breast cancer. Women were randomised (1:1) to standard treatment (chemotherapy followed by endocrine therapy) or to test guided therapy (endocrine therapy alone if low risk, standard treatment if high risk). Oncotype DX was used to direct therapy with a cut-point of >25.
Chemotherapy was selected from regimens commonly used in the NHS.
Molecular tests
Additional molecular tests were conducted on all patients with available samples to enable a 
Economic modelling method
The methods for the economic analysis followed the guidelines and reference case of the UK National Institute of Health and Care Excellence (NICE). 10 The model structure was based on a previously published model, 12 and consists of an initial decision-tree ( Figure 1a ) followed by a seven health-state time-dependent discrete-state transition (modified Markov) cohort model ( Figure 1b ). The model structure was validated through consultation with clinical experts within the trial management group.
Model Parameters
Full details of how the model parameters were defined are provided in the supplementary material (Table S3 ). Briefly, the allocation of patients into high-and low-risk groups was based on the OPTIMA prelim study. Cancer recurrence rates for the OPTIMA-prelim patients were estimated using 10 year forecasts from Adjuvant! Online. 13 The effect of chemotherapy on recurrence free survival dependent on test score was taken from the SWOG 8814 trial by modelling the log hazard ratio for 10 year recurrence free survival as a linear function of the Oncotype DX Recurrence Score (RS). 14 For other tests, representative uncertainty was introduced into the model using an uncertain prior distribution for the predictive effect from which weighted sampling depended on the degree of discordance between the test and Oncotype DX seen in OPTIMA prelim. Chemotherapy procurement, delivery and toxicity costs were taken from the British National Formulary, the NHS Commercial Medicines Unit and NHS Reference costs. [15] [16] [17] The proportions, case-mix and test selection of patients treated with anthracycline plus taxane, anthracycline alone, or taxane alone were modelled directly from the OPTIMA prelim data.
Healthcare costs and quality of life
Costs of cancer recurrence and long term toxicities were taken from a bespoke costing study of NHS patients and the published literature. 18 Quality of life (utility) values were extracted from a previously published study and assigned to each model health state, including a decrement for chemotherapy toxicity. 19
Sensitivity analyses
Probabilistic sensitivity analysis was conducted using Monte Carlo simulation to sample from distributions assigned to model input parameters. In addition, two alternative model specifications were analysed to explore key structural uncertainties:
1. Sensitivity analysis on the chemotherapy effect. The assumption of a predictive treatment effect was challenged in a sensitivity analysis that assumed constant relative benefit from chemotherapy across all risk groups based on the Oxford
Overview meta-analysis applied over a 5-year period. 20 2. Sensitivity analysis on survival after recurrence -in the base-case analysis the survival after distant recurrence was assumed to be constant across groups. In a sensitivity analysis, survival after recurrence was assumed to depend on whether patients had previously received adjuvant chemotherapy.
Value of Information analysis
Value of information analysis is a powerful method for assigning a value to future planned research. [21] [22] [23] It relies on the theory that if the evidence for the effectiveness or costeffectiveness of a new technology is uncertain then we risk making a sub-optimal decision about which to adopt for use in a population of patients. Making a suboptimal adoption decision has the consequence of lost health or lost resources compared to an optimal decision. The reduction in decision uncertainty therefore has quantifiable value. The results of the value of information analysis were presented using the following statistics:
 Expected Net Health Benefit is the central measure of cost-effectiveness expressed in terms of QALYs, assuming a societal willingness to pay threshold value of £20,000 per QALY.
 
Cost-effectiveness results
In the base case analysis the expected lifetime per-patient cost if all patients receive chemotherapy was £13,961 (95% CI £10,535 -£21,203) and the expected lifetime QALYs was 7.69 (95% CI 5.06 -9.58). The mean incremental QALYs with each testing strategy were very similar at between 0.17 and 0.20 more than chemotherapy for all, although credible intervals were generally around plus or minus 1 QALY ( Table 3 ). The mean incremental cost per patient was more variable, between an additional cost of £195 (95% CI £-3,206 -£3,430) with MammaPrint to a saving of £1,892 (95% CI -£5,415 -£1,488) with IHC4 in comparison with all patients receiving chemotherapy. The Net Health Benefit from all testing strategies was higher than for standard care, although was of a very similar magnitude between tests.
Uncertainty in the cost-effectiveness of all tests was large (Figure 2a and Figure 2b ). The probability that individual tests are more cost-effective than standard care ranged from 75%
(MammaPrint) to 81% (IHC4) in separate two-way comparisons. The incremental analysis, in which all tests compete with each other in a multi-way comparison, demonstrated that the probability that test-directed chemotherapy using any test is more cost-effective than standard care was 86% ( Figure 2c ). *'Dominates' implies that the test is more effective and less costly than all patients receiving chemotherapy. **A positive incremental net benefit is necessary for a test to be considered more cost-effective than all patients receiving chemotherapy. The higher the incremental net benefit the more cost-effective the test is expected to be.
Value of Information Analysis
The expected value of perfect information (EVPI), which represents the expected opportunity cost as a consequence of current decision uncertainty is 0. 
Sensitivity analysis -chemotherapy effect
In this analysis treating all patients with chemotherapy was more cost-effective than any of the testing options with a probability of individual tests being cost-effective ranging between 31% and 50% ( Table 3 ). The population EVPI was 4165 QALYs suggesting that further research may be worthwhile even if the chemotherapy effect is thought to be constant. The value of information analysis (Figure 3 ) shows the ranking of tests for research value which is of a notably different order compared with the base case results, suggesting high value into research on all test apart from MammaTyper.
Sensitivity analysis -survival after recurrence
Here it was assumed that post-recurrence survival is dependent on previous treatment with adjuvant chemotherapy and, by association, test score. Oncotype DX is favoured on the basis of expected cost-effectiveness, with Prosigna ROR falling into second place ( Table 3 ). The population EVPI was 2353 QALYs.
DISCUSSION
In the adjuvant treatment of early breast cancer, the notable survival gains seen at population level are at the cost of overtreatment and morbidity for many women, as well as unnecessary healthcare expenditure. Molecular testing offers a new era of enhanced risk stratification and may allow the prediction of which patients benefit, and therefore which patients may safely be spared chemotherapy. The potential efficiencies of such a strategy are very apparent, but the challenges of delivering an evidence base adequate to support adoption of this approach are significant and expensive given the large sample sizes required for RCTs of diagnostic tests. By considering the evidence requirements of not only clinical and scientific decision makers, but also health service and reimbursement decision makers earlier than is usual in the research and development process we have been able to optimise research design and research funding decisions within the OPTIMA programme.
The overarching message is that molecular testing has huge potential both from a clinical and a cost-effectiveness perspective; but currently there is equally substantial uncertainty in the evidence base. There is undisputable value in generating robust evidence into molecular testing in our OPTIMA population and a decision to invest in the proposed trial can clearly be made. What is much less certain is which test is best or most cost effective. Based on the information provided by a future RCT primary endpoint of 5-year recurrence free survival, we have been able to rank different tests based on their research value. While it would be desirable to include all tests in a prospective future trial, the resources required for such would be unfeasible. By focussing future research on tests that offer best research value, we are maximising the chances of taking the correct test into practice in the long run.
The key outcome measures of the OPTIMA prelim economic analysis, as qualified by the value of information analysis, remain unfamiliar to many; but we believe they are the correct metric to answer research questions concerned with the efficient use of limited health care delivery and health research questions. A pitfall that we sought to avoid was the use of statements of effectiveness or cost-effectiveness given the immaturity of much of the data contributing to this analysis. By focussing on decision uncertainty and the risk and consequences of suboptimal decision making we make balanced recommendations about research value, whilst avoiding statements that may prematurely be interpreted as practice-changing. The absence of data directly comparing the clinical validity of tests makes statements about costeffectiveness difficult to make and is an inevitable limitation of undertaking economic evaluation early in the technology development cycle. The quantification of uncertainties and research value is, however, more valid. This is because uncertainty in the comparative performance is quantitatively inflated in the model as a function of discordance with Oncotype DX. As such the ranking of tests for research value is valid, whereas the ranking of tests for cost-effectiveness is more questionable. To clarify this point, note that ultimately a test which always selects patients in an identical manner to Oncotype DX will perform identically and therefore additional test-specific research will have no value. As with any model, it has limitations due to necessary assumptions; for example, late chemotherapy effects such as cardiac toxicity and second malignancies have not explicitly been modelled, survival distributions are assumed to be exponentially distributed and many of the model parameters including costs and quality of life have been derived from the literature, relying on studies that may not be exactly transferable to the setting under study. We hope that may of these limitations will be addressed within the ongoing OPTIMA research programme.
A particularly important conclusion from this study is drawn from the sensitivity analysis which reveals that molecular tests need to predict chemotherapy effect and that prognostication of baseline risk is not enough for them to be cost-effective.
In conclusion, the economic analyses of the OPTIMA prelim trial have demonstrated that there is significant research value in pursuing a fully powered RCT with a 5-year recurrence free survival primary endpoint in the UK in a clinically high risk ER positive population. where logHR = the log hazard ratio for recurrence free survival, alpha = 0.4541 (se 0.03749), beta = -0.0238 (se 0.00418), RS = Recurrence Score and the correlation between alpha and beta is assumed to be -0.5.
The resulting hazard ratio was applied to the no-chemotherapy recurrence rates for all individual patients in the "chemotherapy for all" standard care arm of the model over the first five years. In the "test-directed" arm of the model, the same chemotherapy effect was only applied to patients in the high-risk groups. Where there was no data providing evidence for the predictive ability of alternative tests, extra uncertainty was introduced into the model for these alternative tests depending on the degree of discordance between the test and Oncotype DX. For example, a completely concordant test will have identical predictive ability and therefore no extra uncertainty is introduced. To achieve adequate representation of extra uncertainty, a suitable prior for the chemotherapy effect of the alternative test was required.
In the absence of any informative information this prior treatment effect was represented by a hazard ratio of mean one with a very large standard deviation, assumed to be log-normally distributed. The choice of prior was subject to sensitivity analysis.
In the base case model specification, post-recurrence survival was assumed to be independent of pre-treatment with adjuvant chemotherapy: the annual post-recurrence probability of death was assumed to be constant across groups with a mean of 0.30 (SD 0.22). 
Chemotherapy treatment and toxicity
The proportions of patients treated with anthracycline plus taxane, anthracycline alone, or taxane alone were estimated from OPTIMA prelim data. Chemotherapy toxicity rates were estimated from landmark chemotherapy clinical trials (Table S2 ). [2] [3] [4] Toxicity rates for FEC100-Pw were assumed to be equivalent to FEC100-T, and toxicity rates for epirubicin (E) were assumed to be equivalent to FEC. Toxicity rates for FEC75 were assumed to be equivalent to two-thirds the rates for FEC100. 
Late effects
Parameters are included in Table S3 (Table . Population age and gender-specific incidence of congestive heart failure were taken from Office of National Statistics published data as presented by the British Heart Foundation. 5 The lifetime relative risk of congestive cardiac failure after chemotherapy was based on data from the Oxford Overviews and applied to the population incidence, to provide an estimate of excess congestive heart failure due to chemotherapy. 6 Mortality after onset of congestive cardiac failure was taken from a UK population study. 7 The age and gender-specific incidence rate of acute myeloid leukaemia was taken from a large UK primary care derived population database. 8 There is evidence for an increased relative risk of acute myeloid leukaemia in patients treated with chemotherapy from a number of published pooled trial-based analyses, but this was difficult to estimate reliably due to the low absolute numbers of observed events. 6, [9] [10] [11] [12] A relative risk of two was therefore specified in the model, but was assigned a very high standard error to reflect this uncertainty. Survival after a diagnosis of acute myeloid leukaemia was based on UK Cancer Registry statistics, as provided in a report by the Northern and Yorkshire Cancer Registration and Information Service (NYCRIS). 13 Other transition probabilities and proportions
The mean time from metastatic recurrence to death was estimated from a UK patient level analysis of 1000 consecutive breast cancer patients in a single NHS Trust with a minimum of ten years follow-up. 14  50% of toxicity-related hospital admissions were assumed to be greater than two days (long stay) and 50% were assumed to be less than two days (short stay)  15% of patients have a central line inserted (but associated complications of this are not costed).
 Community healthcare costs, out-of-pocket patient and carer costs, and costs due to future lost-productivity are not included.
 Value Added Tax (VAT) is not included on drug costs.
Unit costs for on-chemotherapy grade 3 and 4 toxicity were taken from the UK NHS reference costs. 17 A full breakdown of chemotherapy costs is given in Tables S4 to S7. Assumes average surface area of 1.7m2 and a relative dose intensity of 92%. 1 cycle of Pw = 3 doses given weekly. The mean annual costs of disease-free and cancer recurrence health states were estimated from an updated audit of hospital income recorded (Table S8 ). 18 These costs are based on the national Payment by Results tariff produced by the UK Department of Health specific to each year in which they were incurred, adjusted for inflation to the base year for the analysis.
Patient data was censored at last follow-up contact and the Kaplan-Meier Sample Average cost method was used to adjust for censoring. 19 The annual cost of the disease-free state was based on year two onwards costs under the assumption that this represents the costs of follow-up minus chemotherapy costs. 
Test costs
Test costs were calculated on a per sample basis using current list prices and data from manufacturers. Where a list price was not available in the public domain, the manufacturers were asked for an expected UK price. Any anticipated NHS discounts were not considered.
Any assumptions used in the cost calculations were based on expert opinion. Costs were converted to 2013 pound sterling (GBP £) using the following exchange rates: GBP to EURO (€) = 0.825, and USD ($) to GBP = 0.60.
All tests were assumed to be exempt from VAT: for tests conducted within the NHS it was As there remains uncertainty about this estimate, which is based on expert opinion, therefore it will be represented as an uncertain parameter in the OPTIMA model, with mean £152 and interquartile range £116 -£207 (sd 69) (implying that there is a 50% chance that the true cost lies within this range). Represented in the model by a lognormal distribution with parameters mu=4.93 and sigma=0.429
Utilities A literature review was carried out to update the relevant health utility values for the OPTIMA model from a previously published relevant systematic review (Table S9 ). 20 Full details of the search strategy, literature review method and data extraction are available on request. Chemotherapy benefit from the Oxford Overview meta-analysis was applied to the predicted recurrence-free survival (RFS) over a 5-year period for patients receiving chemotherapy in the model. The hazard ratio for RFS for anthracycline chemotherapy was taken to be 0.69 (SE 0.04) over the first 5 years with an additional benefit from the addition of a taxane of 0.84 (95%CI 0.78-0.91). 6 A limitation of this approach is that it only allows incorporation of uncertainty around the forecast where full information is available about the prognostic model; such information is not available for Adjuvant!. Therefore, in an attempt to represent likely uncertainty, the sample standard deviation of the Adjuvant! RFS estimates was taken as a proxy for the standard error of individual estimates.
Sensitivity Analysis 2: Survival after cancer recurrence varies depending on whether patients received chemotherapy as adjuvant therapy for their early cancer.
It is likely that patients who have received adjuvant chemotherapy will survive for a different length of time after a recurrence compared to those who did not receive adjuvant chemotherapy. In the base-case the annual post-recurrence probability of death was assumed to be 0.30 (SD 0.22). In sensitivity analysis 2 the annual probability of death after recurrence varied depending on whether previous adjuvant chemotherapy had been given.
Given that overall survival is available for the SWOG88-14 trial, the post-recurrence survival parameter was derived by calibrating the economic model against this outcome measure.
The resulting annual probability of death following recurrence is therefore 0.40 (standard deviation (SD) 0.17) for patients treated with adjuvant chemotherapy and 0.14 (SD 0.17) for patients who did not receive adjuvant chemotherapy and who had a low Oncotype DX RS.
Section 3: Incident population calculations for value of information analysis
There is very little evidence to inform this parameter in the relevant patient populations.
Given that overall survival is available for the SWOG88-14 trial, the post-recurrence survival parameter was derived by calibrating the model against this outcome measure. The resulting annual probability of death following recurrence is therefore 0.40 (standard deviation (SD) 0.17) for patients treated with adjuvant chemotherapy and 0.14 (SD 0.17) for patients who did not receive adjuvant chemotherapy and who had a low Oncotype DX RS.
In order to provide an estimate of total value of information an estimate of number of patients for whom the reimbursement decision is pertinent is required. Based on information provided by the West-midlands cancer registration service, the annual incident population of patients eligible for OPTIMA in England alone is around 4376 patients (Table S10 ). It should be noted that the quality of cancer registration data is higher in the West-midlands region than other regions. The West-Midlands population diagnosed of breast cancer represents 10.9% of the total English population of patients diagnosed with breast cancer. English estimates are therefore based on a multiple of the West-Midlands estimate rather than data for the whole of England. The pertinent time horizon for the decision problem was assumed to be ten years.
